Abstract
Neoadjuvant treatment has been widely adopted for the management of patients with triple-negative breast cancer (TNBC). However, the addition of platinum-based drugs to standard neoadjuvant chemotherapy (NAC) is still a matter of controversy. This study aims to explore the outcomes of patients with TNBC following NAC with anthracycline/taxane-based regimens (AC±T) plus carboplatin (CB).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
